CD274 and breast carcinoma: recently developed a biodegradable cationic polymer of poly(β‐amino esters) to deliver CRISPR/Cas9 plasmids target Cyclin‐dependent kinase 5 gene to reduce PD‐L1 expression in tumor cells, which demonstrated favorable therapeutic efficacy in mouse melanoma and breast cancer models.[14] Other nonviral carriers such as supramolecular cationic gold nanorod,[15] polyethylenimine derivatives,[16, 17, 18] and mesoporous silica nanoparticle[19] have also been exploited to deliver CRISPR/Cas9 components for PD‐L1 gene editing.